Pharmacists have an opening to close chronic kidney disease (CKD) medication gaps as generic ACE inhibitors, ARBs, and SGLT2 inhibitors go underused.
Caroline Pearson
Advertisement
Articles by Caroline Pearson
A Peterson Health Technology Institute evaluation found virtual chronic kidney disease (CKD) care companies aren’t slowing kidney function decline or boosting medication adherence, despite billions invested.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
3
CKD Prevalence Unmoved Despite Billions in Virtual Care
4
Why 5 Injectable Drugs Have Been in Shortage for More Than a Decade
5